跳至主要内容
临床试验/NCT03772457
NCT03772457招募中不适用

To Explore the Predictive Value of Infarction Volume on Hemorrhagic Transformation in Newly Diagnosed Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2019年1月18日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
400
试验地点
1
主要终点
Susceptibility weighted imaging(SWI) detection of newly developed hemorrhagic transformation after 14 days of rivaroxaban treatment

研究概览

简要总结

This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female, age≥18;
  • Were newly diagnosed asischemic stroke/TIA concomitant NVAF;
  • Prescribedand accept Rivaroxaban;
  • Sign thewritten informed consent.

排除标准

  • Renal impairment (CrCl<15 ml/min) or severe hepatic impairment.
  • Significant hemorrhagic transformation (parenchymal hematoma type I or type II by the ECASS definition).
  • Stroke or TIA caused by large artery atherosclerosis
  • Planned major surgery or invasive intervention
  • Active internal bleeding
  • Malignancy or other serious medical conditions with a life expectancy <6 months
  • Allergery to Rivaroxaban
  • Pregnancy or breast-feeding

结局指标

主要结局

Susceptibility weighted imaging(SWI) detection of newly developed hemorrhagic transformation after 14 days of rivaroxaban treatment

时间窗: 14 days after enrolling

次要结局

未报告次要终点

研究者

发起方
Second Affiliated Hospital, School of Medicine, Zhejiang University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验